A new treatment for endometrial cancer with gonadotrophin releasing‐hormone analogue

BJOG: An International Journal of Obstetrics and Gynaecology - Tập 98 Số 10 - Trang 1037-1041 - 1991
C. Gallagher1, R.T.D. Oliver1, David Oram2, C. G. FOWLER3, Peter Blake4, B.S. Mantell5, M L Slevin6, H. F. Hope-Stone5
1Department of Medical Oncology, The Royal London Hospital, Whitechapel Road, London E1 1BB
2Department of Gynaecology, The Royal London Hospital, Whitechapel Road, London E1 1BB
3Department of Urology, The Royal London Hospital, Whitechapel Road, London E1 1BB
4Department of Radiotherapy, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ
5Department of Radiotherapy and Oncology, The Royal London Hospital, Whitechapel Road, London E1 1BB
6Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE

Tóm tắt

AbstractObjective— To test the antitumour effect of gonadotrophin releasing‐hormone (GnRH) analogues in women with recurrent endometrial cancer.Design— An open phase II observational trial of GnRH analogues. Serial measurements of gonadotrophins, sex hormones and tumour dimensions were made together with repeat biopsy when possible to assess the response to treatment.Setting— The outpatient clinics of the Department of Medical Oncology at The Royal London, Royal Marsden and St Bartholomew's hospitals.Subjects— 17 patients with endometrial cancer which had recurred after surgery, radiotherapy and progesterone treatment and was symptomatic, progressive and assessable for response.Intervention— Monthly subcutaneous injection of GnRH analogue.Main outcome measures— Reduction in serum gonadotrophins and reduction in tumour dimensions.Results— Six out of 17 patients (35%, 95% CI 12.6–58%) achieved a complete or partial remission which continues for a median of 20 months with no adverse effects.Conclusion— GnRH analogues have a significant antitumour effect in recurrent endometrial cancer which warrants further examination in comparison with progestogens.

Từ khóa


Tài liệu tham khảo

10.1016/0090-8258(87)90273-3

10.1210/jcem-59-1-119

10.1016/0090-8258(89)90514-3

10.1016/S0140-6736(87)92100-3

10.1073/pnas.69.1.278

Cao Yongqing, 1984, Identification and characterization of luteinizing hormone releasing hormone (LH‐RH) receptors in the endometrial tissue of pregnant rats, Scientia Sinica, 27, 687

10.1016/0002-9378(86)90358-3

Edmonson K. H., 1986, Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment, Cancer Treat Rep, 70, 1019

10.1016/0360-3016(89)90367-2

10.1038/bjc.1989.19

10.1200/JCO.1985.3.8.1068

10.1210/edrv-2-4-437

10.1200/JCO.1989.7.1.115

Kelley R. M., 1965, Role of progesterone in human endometrial cancer, Cancer Res, 25, 1190

LeeY. J.(1986)Phase 2 trials in cancer: present status and analysis methods.Drugs Expl Clin Res 57–71.

10.1016/0090-8258(89)90624-0

10.1016/0006-291X(71)90491-8

10.1038/313231a0

10.1007/BF00931402

10.1136/bmj.296.6631.1229

10.1210/jcem-70-4-1173

10.1097/00006250-198602000-00019

10.1016/0006-291X(83)90844-6

10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

10.1210/jcem-51-4-873

10.1016/0090-8258(74)90029-8

10.1210/jcem-70-2-421

10.1007/BF00931381

10.1016/0090-4295(85)90523-0

Srkalovic G., 1990, Detection and partial characterization of receptors for [D‐Trp‐6]‐luteinizing hormone releasing hormone and epidermal growth factor in human endometrial carcinoma, Cancer Res, 50, 1841

10.1056/NEJM197907123010211

Thông tin
Thông tin xuất bản

BJOG: An International Journal of Obstetrics and Gynaecology

Tập 98 Số 10

1037-1041

Thông tin tác giả